Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 107 Carcinoma, Renal Cell 74 Neoplasm Metastasis 48 Neoplasms 37 Neuroendocrine Tumors 35 Kidney Neoplasms 27 Recurrence 19 Tuberous Sclerosis 18 Carcinoma, Non-Small-Cell Lung 17 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Lymphoma 15 Lymphoma, Mantle-Cell 14 Lymphoma, Large B-Cell, Diffuse 14 Head and Neck Neoplasms 14 Glioblastoma 14 Carcinoma, Hepatocellular 14 Colorectal Neoplasms 13 Stomach Neoplasms 12 Lung Neoplasms 12 Leukemia, Lymphocytic, Chronic, B-Cell 12 Hodgkin Disease 12 Brain Neoplasms 12 Sarcoma 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Pancreatic Neoplasms 11 Glioma 11 Waldenstrom Macroglobulinemia 10 Lymphoma, Follicular 10 Carcinoma, Neuroendocrine 10

Interventions

mirdametinib 2 tipifarnib 1 talimogene laherparepvec 1 peginterferon alfa-2b 1 nilotinib 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vincristine 1 Temozolomide 1 Talaporfin 1 Sirolimus 1 Restraint, Physical 1 Ranibizumab 1 Radiosurgery 1 Photochemotherapy 1 Neurofibromin 1 1 Mn-PyC3A 1 Imatinib Mesylate 1 Everolimus 1 Elasticity Imaging Techniques 1 Deoxycholic Acid 1 Cryotherapy 1 Celecoxib 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibroma × Everolimus × Clear all

NCT02332902 2023-12-20

DCLNF1

The University of Texas Health Science Center, Houston

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡